Trial Profile

A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 13 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Baricitinib (Primary)
Indications Systemic lupus erythematosus
Focus Adverse reactions; Registrational
Acronyms SLE-BRAVE-X
Sponsors Eli Lilly and Company; Eli Lilly Japan

Most Recent Events

11 May 2022 Status changed from active, no longer recruiting to discontinued.
28 Apr 2022 This trial has been completed in Netherlands and Poland (Date of the global end of the trial : 01-Apr-2022), according to European Clinical Trials Database record.
22 Apr 2022 This trial has been completed in Greece (Global end date: 1 Apr 2022).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com